| 194.28 -2.27 (-1.15%) | 10-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 247.04 | 1-year : | 288.54 |
| Resists | First : | 211.5 | Second : | 247.04 |
| Pivot price | 194.31 |
|||
| Supports | First : | 189.56 | Second : | 176 |
| MAs | MA(5) : | 187.98  |
MA(20) : | 196.54 |
| MA(100) : | 190.04 |
MA(250) : | 136.91 |
|
| MACD | MACD : | -3.4 |
Signal : | -3.1 |
| %K %D | K(14,3) : | 42.7 |
D(3) : | 29 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 224.3 | Low : | 52.47 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RVMD ] has closed above bottom band by 49.1%. Bollinger Bands are 31% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 203.71 - 204.88 | 204.88 - 205.93 |
| Low: | 191.36 - 192.59 | 192.59 - 193.71 |
| Close: | 192.24 - 194.21 | 194.21 - 195.99 |
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Wed, 21 Oct 2026
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026 - Yahoo Finance
Tue, 20 Oct 2026
RVMD Stock Rallies As RASONQUE Launch And EU Nod Fuel Hype - Timothy Sykes
Tue, 20 Oct 2026
Revolution Medicines Inc Stock (RVMD) Moved Up by 7.41% on Oct 20: Facts Behind the Movement - TradingKey
Tue, 20 Oct 2026
Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment - Benzinga
Tue, 20 Oct 2026
Revolution Medicines (RVMD) Has an Approved Cancer Drug. Can Its $38 Billion Valuation Deliver? - Yahoo Finance
Tue, 20 Oct 2026
RVMD Stock Rides RASONQUE Momentum As Analysts Hike Targets - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 214 (M) |
| Shares Float | 185 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 101.2 (%) |
| Shares Short | 11,930 (K) |
| Shares Short P.Month | 9,730 (K) |
| EPS | -8.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.2 % |
| Return on Equity (ttm) | -79.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -6.07 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1,220 (M) |
| Levered Free Cash Flow | -712 (M) |
| PE Ratio | -21.68 |
| PEG Ratio | 0 |
| Price to Book value | 15.95 |
| Price to Sales | 0 |
| Price to Cash Flow | -34.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|